BindingDB logo
myBDB logout

BDBM50199491 1-(6-((2H-tetrazol-5-yl)carbamoyl)-1,2,3,4-tetrahydronaphthalen-1-yl)-1-((1r,4r)-4-tert-butylcyclohexyl)-3-(4-(trifluoromethoxy)phenyl)urea::CHEMBL411831

SMILES: CC(C)(C)[C@H]1CC[C@@H](CC1)N(C1CCCc2cc(ccc12)C(=O)Nc1nnn[nH]1)C(=O)Nc1ccc(OC(F)(F)F)cc1

InChI Key: InChIKey=CHYPABFSTPTACZ-DUNBPCILSA-N

Data: 5 IC50

Find this compound or compounds like it in BindingDB or PDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 5 hits for monomerid = 50199491   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kcal/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Glucagon receptor


(Homo sapiens (Human))
BDBM50199491
PNG
(1-(6-((2H-tetrazol-5-yl)carbamoyl)-1,2,3,4-tetrahy...)
Show SMILES CC(C)(C)[C@H]1CC[C@@H](CC1)N(C1CCCc2cc(ccc12)C(=O)Nc1nnn[nH]1)C(=O)Nc1ccc(OC(F)(F)F)cc1 |w:11.11,wU:7.10,wD:4.3,(22,-37.36,;22.01,-35.83,;23.55,-35.83,;20.47,-35.82,;22.01,-34.29,;23.35,-33.52,;23.35,-31.97,;22.03,-31.21,;20.68,-31.98,;20.68,-33.51,;22.03,-29.67,;23.36,-28.89,;23.35,-27.35,;24.7,-26.58,;26.04,-27.35,;26.03,-28.9,;27.35,-29.65,;27.35,-31.2,;26.02,-31.97,;24.69,-31.2,;24.69,-29.67,;28.69,-31.97,;28.69,-33.51,;30.02,-31.2,;31.36,-31.96,;31.53,-33.49,;33.04,-33.81,;33.8,-32.47,;32.77,-31.33,;20.69,-28.9,;20.69,-27.36,;19.36,-29.67,;18.03,-28.9,;16.68,-29.68,;15.35,-28.9,;15.35,-27.36,;14.02,-26.59,;14.02,-25.05,;14,-23.51,;15.56,-25.04,;12.48,-25.06,;16.68,-26.59,;18.02,-27.35,)|
Show InChI InChI=1S/C30H36F3N7O3/c1-29(2,3)20-8-12-22(13-9-20)40(28(42)34-21-10-14-23(15-11-21)43-30(31,32)33)25-6-4-5-18-17-19(7-16-24(18)25)26(41)35-27-36-38-39-37-27/h7,10-11,14-17,20,22,25H,4-6,8-9,12-13H2,1-3H3,(H,34,42)(H2,35,36,37,38,39,41)/t20-,22-,25?
PDB
MMDB

UniProtKB/SwissProt

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/a 1.05E+3n/an/an/an/an/an/a



Merck Research Laboratories

Curated by ChEMBL


Assay Description
Antagonist activity at human glucagon receptor transfected in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation


Bioorg Med Chem Lett 17: 587-92 (2007)


Article DOI: 10.1016/j.bmcl.2006.11.014
BindingDB Entry DOI: 10.7270/Q2N58M0Q
More data for this
Ligand-Target Pair
Gastric inhibitory polypeptide receptor


(Homo sapiens (Human))
BDBM50199491
PNG
(1-(6-((2H-tetrazol-5-yl)carbamoyl)-1,2,3,4-tetrahy...)
Show SMILES CC(C)(C)[C@H]1CC[C@@H](CC1)N(C1CCCc2cc(ccc12)C(=O)Nc1nnn[nH]1)C(=O)Nc1ccc(OC(F)(F)F)cc1 |w:11.11,wU:7.10,wD:4.3,(22,-37.36,;22.01,-35.83,;23.55,-35.83,;20.47,-35.82,;22.01,-34.29,;23.35,-33.52,;23.35,-31.97,;22.03,-31.21,;20.68,-31.98,;20.68,-33.51,;22.03,-29.67,;23.36,-28.89,;23.35,-27.35,;24.7,-26.58,;26.04,-27.35,;26.03,-28.9,;27.35,-29.65,;27.35,-31.2,;26.02,-31.97,;24.69,-31.2,;24.69,-29.67,;28.69,-31.97,;28.69,-33.51,;30.02,-31.2,;31.36,-31.96,;31.53,-33.49,;33.04,-33.81,;33.8,-32.47,;32.77,-31.33,;20.69,-28.9,;20.69,-27.36,;19.36,-29.67,;18.03,-28.9,;16.68,-29.68,;15.35,-28.9,;15.35,-27.36,;14.02,-26.59,;14.02,-25.05,;14,-23.51,;15.56,-25.04,;12.48,-25.06,;16.68,-26.59,;18.02,-27.35,)|
Show InChI InChI=1S/C30H36F3N7O3/c1-29(2,3)20-8-12-22(13-9-20)40(28(42)34-21-10-14-23(15-11-21)43-30(31,32)33)25-6-4-5-18-17-19(7-16-24(18)25)26(41)35-27-36-38-39-37-27/h7,10-11,14-17,20,22,25H,4-6,8-9,12-13H2,1-3H3,(H,34,42)(H2,35,36,37,38,39,41)/t20-,22-,25?
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/a 178n/an/an/an/an/an/a



Merck Research Laboratories

Curated by ChEMBL


Assay Description
Antagonist activity at human GIP receptor transfected in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation


Bioorg Med Chem Lett 17: 587-92 (2007)


Article DOI: 10.1016/j.bmcl.2006.11.014
BindingDB Entry DOI: 10.7270/Q2N58M0Q
More data for this
Ligand-Target Pair
Glucagon receptor


(Homo sapiens (Human))
BDBM50199491
PNG
(1-(6-((2H-tetrazol-5-yl)carbamoyl)-1,2,3,4-tetrahy...)
Show SMILES CC(C)(C)[C@H]1CC[C@@H](CC1)N(C1CCCc2cc(ccc12)C(=O)Nc1nnn[nH]1)C(=O)Nc1ccc(OC(F)(F)F)cc1 |w:11.11,wU:7.10,wD:4.3,(22,-37.36,;22.01,-35.83,;23.55,-35.83,;20.47,-35.82,;22.01,-34.29,;23.35,-33.52,;23.35,-31.97,;22.03,-31.21,;20.68,-31.98,;20.68,-33.51,;22.03,-29.67,;23.36,-28.89,;23.35,-27.35,;24.7,-26.58,;26.04,-27.35,;26.03,-28.9,;27.35,-29.65,;27.35,-31.2,;26.02,-31.97,;24.69,-31.2,;24.69,-29.67,;28.69,-31.97,;28.69,-33.51,;30.02,-31.2,;31.36,-31.96,;31.53,-33.49,;33.04,-33.81,;33.8,-32.47,;32.77,-31.33,;20.69,-28.9,;20.69,-27.36,;19.36,-29.67,;18.03,-28.9,;16.68,-29.68,;15.35,-28.9,;15.35,-27.36,;14.02,-26.59,;14.02,-25.05,;14,-23.51,;15.56,-25.04,;12.48,-25.06,;16.68,-26.59,;18.02,-27.35,)|
Show InChI InChI=1S/C30H36F3N7O3/c1-29(2,3)20-8-12-22(13-9-20)40(28(42)34-21-10-14-23(15-11-21)43-30(31,32)33)25-6-4-5-18-17-19(7-16-24(18)25)26(41)35-27-36-38-39-37-27/h7,10-11,14-17,20,22,25H,4-6,8-9,12-13H2,1-3H3,(H,34,42)(H2,35,36,37,38,39,41)/t20-,22-,25?
PDB
MMDB

UniProtKB/SwissProt

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/a 148n/an/an/an/an/an/a



Merck Research Laboratories

Curated by ChEMBL


Assay Description
Displacement of [125]glucagon from human glucagon receptor expressed in CHO cells


Bioorg Med Chem Lett 17: 587-92 (2007)


Article DOI: 10.1016/j.bmcl.2006.11.014
BindingDB Entry DOI: 10.7270/Q2N58M0Q
More data for this
Ligand-Target Pair
Glucagon receptor


(Homo sapiens (Human))
BDBM50199491
PNG
(1-(6-((2H-tetrazol-5-yl)carbamoyl)-1,2,3,4-tetrahy...)
Show SMILES CC(C)(C)[C@H]1CC[C@@H](CC1)N(C1CCCc2cc(ccc12)C(=O)Nc1nnn[nH]1)C(=O)Nc1ccc(OC(F)(F)F)cc1 |w:11.11,wU:7.10,wD:4.3,(22,-37.36,;22.01,-35.83,;23.55,-35.83,;20.47,-35.82,;22.01,-34.29,;23.35,-33.52,;23.35,-31.97,;22.03,-31.21,;20.68,-31.98,;20.68,-33.51,;22.03,-29.67,;23.36,-28.89,;23.35,-27.35,;24.7,-26.58,;26.04,-27.35,;26.03,-28.9,;27.35,-29.65,;27.35,-31.2,;26.02,-31.97,;24.69,-31.2,;24.69,-29.67,;28.69,-31.97,;28.69,-33.51,;30.02,-31.2,;31.36,-31.96,;31.53,-33.49,;33.04,-33.81,;33.8,-32.47,;32.77,-31.33,;20.69,-28.9,;20.69,-27.36,;19.36,-29.67,;18.03,-28.9,;16.68,-29.68,;15.35,-28.9,;15.35,-27.36,;14.02,-26.59,;14.02,-25.05,;14,-23.51,;15.56,-25.04,;12.48,-25.06,;16.68,-26.59,;18.02,-27.35,)|
Show InChI InChI=1S/C30H36F3N7O3/c1-29(2,3)20-8-12-22(13-9-20)40(28(42)34-21-10-14-23(15-11-21)43-30(31,32)33)25-6-4-5-18-17-19(7-16-24(18)25)26(41)35-27-36-38-39-37-27/h7,10-11,14-17,20,22,25H,4-6,8-9,12-13H2,1-3H3,(H,34,42)(H2,35,36,37,38,39,41)/t20-,22-,25?
PDB
MMDB

UniProtKB/SwissProt

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/a 0.5n/an/an/an/an/an/a



Merck Research Laboratories

Curated by ChEMBL


Assay Description
Displacement of [125]glucagon from human glucagon receptor expressed in CHO cells


Bioorg Med Chem Lett 17: 587-92 (2007)


Article DOI: 10.1016/j.bmcl.2006.11.014
BindingDB Entry DOI: 10.7270/Q2N58M0Q
More data for this
Ligand-Target Pair
Glucagon receptor


(Homo sapiens (Human))
BDBM50199491
PNG
(1-(6-((2H-tetrazol-5-yl)carbamoyl)-1,2,3,4-tetrahy...)
Show SMILES CC(C)(C)[C@H]1CC[C@@H](CC1)N(C1CCCc2cc(ccc12)C(=O)Nc1nnn[nH]1)C(=O)Nc1ccc(OC(F)(F)F)cc1 |w:11.11,wU:7.10,wD:4.3,(22,-37.36,;22.01,-35.83,;23.55,-35.83,;20.47,-35.82,;22.01,-34.29,;23.35,-33.52,;23.35,-31.97,;22.03,-31.21,;20.68,-31.98,;20.68,-33.51,;22.03,-29.67,;23.36,-28.89,;23.35,-27.35,;24.7,-26.58,;26.04,-27.35,;26.03,-28.9,;27.35,-29.65,;27.35,-31.2,;26.02,-31.97,;24.69,-31.2,;24.69,-29.67,;28.69,-31.97,;28.69,-33.51,;30.02,-31.2,;31.36,-31.96,;31.53,-33.49,;33.04,-33.81,;33.8,-32.47,;32.77,-31.33,;20.69,-28.9,;20.69,-27.36,;19.36,-29.67,;18.03,-28.9,;16.68,-29.68,;15.35,-28.9,;15.35,-27.36,;14.02,-26.59,;14.02,-25.05,;14,-23.51,;15.56,-25.04,;12.48,-25.06,;16.68,-26.59,;18.02,-27.35,)|
Show InChI InChI=1S/C30H36F3N7O3/c1-29(2,3)20-8-12-22(13-9-20)40(28(42)34-21-10-14-23(15-11-21)43-30(31,32)33)25-6-4-5-18-17-19(7-16-24(18)25)26(41)35-27-36-38-39-37-27/h7,10-11,14-17,20,22,25H,4-6,8-9,12-13H2,1-3H3,(H,34,42)(H2,35,36,37,38,39,41)/t20-,22-,25?
PDB
MMDB

UniProtKB/SwissProt

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/a 11n/an/an/an/an/an/a



Merck Research Laboratories

Curated by ChEMBL


Assay Description
Antagonist activity at human glucagon receptor transfected in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation


Bioorg Med Chem Lett 17: 587-92 (2007)


Article DOI: 10.1016/j.bmcl.2006.11.014
BindingDB Entry DOI: 10.7270/Q2N58M0Q
More data for this
Ligand-Target Pair